Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company leveraging a deep understanding of immunobiology to ...

The following is a summary of "ADORA2B promotes proliferation and migration in head and neck squamous cell carcinoma and is ...

T-cell activation involves two phases, enabling a more precise immune response. This insight may boost cancer immunotherapy ...

Targeting a newly discovered vulnerability in the signals that cyst nematodes use to infect plant roots could be a powerful ...

A replay of the webcast of the R&D investor event is available on the “Events” page in the “Investor Relations & Media” section of the Company’s website at ...

EpiVax, Inc. announces a new study published in Frontiers in Immunology unveiling the impact of peptides known as "Tregitopes ...

CAR T-cell therapy showed encouraging efficacy and good safety in newly diagnosed Ph-positive ALL,” the researchers wrote.

Antibodies are best known for their ability to latch onto and neutralize bacteria, viruses and other pathogens. But these ...

Mark Litzow, MD, discusses the challenges of using immunotherapy for the treatment of acute lymphoblastic leukemia.

Vaccinex (VCNX) will present exciting new data characterizing the unique mechanism of pepinemab to enhance immune responses to checkpoint ...

Although patients receiving CAR-T therapies are frequently hospitalized given risks of cytokine release syndrome (CRS) and immune effector cell–associated neurotoxicity syndrome (ICANS), there is ...